3D illustration of the human heart and circulatory system. Credit: Bryan Brandenburg.

US-based medical device firm Cardialen has raised new funds in a series B investment round for the development of an implantable defibrillation therapy to gently restore normal heart rhythm.

The $17m financing round was led by RiverVest Venture Partners. Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital also joined the round.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cardialen plans to use the new funds to further develop its clinical unpinning termination (UPT) therapy programmed with additional human testing. It also seeks to support the development of an implant.

“This treatment option is expected to provide a low-energy alternative for existing high-energy defibrillators via more tolerable and less debilitating therapy for heart rhythm disorders.”

Cardialen president and CEO Jeff Peters said: “This round of financing gives Cardialen the capital to establish acute safety of UPT therapy for the treatment of various tachyarrhythmias.”

The UPT therapy is designed to deliver a series of low-energy electrical pulses in order to restore abnormal heart rates to normal.

This treatment option is expected to provide a low-energy alternative for existing high-energy defibrillators via more tolerable and less debilitating therapy for heart rhythm disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In early human feasibility studies, the Cardialen UPT therapy is said to have demonstrated the potential for successful treatment of cardiac arrhythmias with substantially lower energy therapy.

Cardialen founder and scientific advisor Igor Efimov said: “Today’s implantable defibrillator therapy generates painful high-energy shocks that are associated with undesirable mortality that is expected to be reduced for patients receiving fewer shocks or a low-energy therapy.

“Our goal with UPT therapy is to reduce the negative effects of high-energy therapy and provide a better quality of life for patients.”

Based on the initial data, the implantable heart therapy is expected to cater to both current and potential defibrillator market.